We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

4 hedge funds and large institutions have $4.51M invested in Plus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0% less capital invested

Capital invested by funds: $4.53M → $4.51M (-$18.8K)

22% less call options, than puts

Call options by funds: $36K | Put options by funds: $46K

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
$36K
Puts
$46K
Net Calls
-$10K
Net Calls Change
+$11K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$617K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$309K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$617K
2
Goldman Sachs
Goldman Sachs
New York
-$27K
3
Wolverine Trading
Wolverine Trading
Illinois
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$2.03M -$617K -2 -22%
PCM
2
Perkins Capital Management
Minnesota
$703K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$539K +$309K +1 +100%
BlackRock
4
BlackRock
New York
$495K +$617K +2 New
Creative Planning
5
Creative Planning
Kansas
$125K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$97K – – –
Northern Trust
7
Northern Trust
Illinois
$89K – – –
Jacobs Levy Equity Management
8
Jacobs Levy Equity Management
New Jersey
$74K – – –
VKH
9
Virtu KCG Holdings
New York
$73K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$64K – – –
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$40K – – –
Simplex Trading
12
Simplex Trading
Illinois
$38K – – –
FPF
13
FNY Partners Fund
New York
$29K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$25K – – –
HighTower Advisors
15
HighTower Advisors
Illinois
$25K – – –
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$21K – – –
UB
17
UMB Bank
Missouri
$20K – – –
UBS Group
18
UBS Group
Switzerland
$6K – – –
New York State Common Retirement Fund
19
New York State Common Retirement Fund
New York
$5K – – –
Morgan Stanley
20
Morgan Stanley
New York
$4K – – –
IP
21
Intellectus Partners
California
$3K – – –
Barclays
22
Barclays
United Kingdom
$2K – – –
Bank of America
23
Bank of America
North Carolina
$1K – – –
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
Wells Fargo
25
Wells Fargo
California
$1K – – –
1
2

PSTV Hedge Fund Activity: Q1 2017 in Review

4 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2017, worth a combined $4.51M — down 0.41% from $4.53M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PSTV positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $617K. The largest seller was Sabby Management, cutting an estimated $617K.

  • 4 institutional investors held Plus Therapeutics (PSTV) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $4.51M of Plus Therapeutics stock for Q1 2017, down 0.41% quarter-over-quarter.
  • 1 fund opened new Plus Therapeutics positions in Q1 2017 and 0 closed out, a net change of +1 holder.
  • The largest Plus Therapeutics buyer in Q1 2017 was BlackRock, an estimated $617K added.
  • The largest Plus Therapeutics seller in Q1 2017 was Sabby Management, an estimated $617K sold.

Based on aggregated 13F filings for Q1 2017.